Trial Profile

Retrospective Cohort Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rimegepant (Primary)
Indications Migraine
Focus Adverse reactions
Sponsors Pfizer

Most Recent Events

05 Mar 2025 Planned number of patients changed from 8082 to 1.
16 Oct 2023 Inclusion and exclusion criteria are updated to decrease the upper and lower age limits from 18 - 55 years to 16 - 49 years. Planned patient enrollment is increased.
16 Oct 2023 Planned number of patients changed from 4020 to 8082.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com